Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Interactive Tools
Sponsored
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Sharyn N. Lewin, MD, Holy Name Medical Center
home
Articles
Systemic Management of Ovarian Cancer: Closing Thoughts
May 27th 2020
Novel Combination Strategies in Recurrent Ovarian Cancer
May 27th 2020
Recurrent Ovarian Cancer: Novel Agents Under Investigation
May 27th 2020
Bevacizumab’s Role in Recurrent Ovarian Cancer
May 27th 2020
Recurrent Ovarian Cancer: Choosing a PARP Inhibitor
May 27th 2020
PARP Inhibition’s Role in Recurrent Ovarian Cancer
May 27th 2020
Frontline Ovarian Cancer Management: Ongoing Clinical Trials
May 27th 2020
Considerations for the JAVELIN OVARIAN 100 Study
May 27th 2020
Ovarian Cancer: Maintenance Following Frontline Bevacizumab
May 27th 2020
Ovarian Cancer: Updates to NCCN Guidelines
May 27th 2020
Treating Ovarian Cancer Based on HRD Status
May 27th 2020
Ovarian Cancer: What is the Role of HRD Testing?
May 27th 2020
Ovarian Cancer: Factors in Deciding on Maintenance Therapy
May 27th 2020
PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer
May 27th 2020
Practical Applications of PRIMA in Ovarian Cancer Management
May 27th 2020
PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
May 27th 2020
SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer
May 27th 2020
GOG-0218: Frontline Bevacizumab in Ovarian Cancer
May 27th 2020